



ACC.14

TCT@ACC-12 | innovation in intervention

A750

JACC April 1, 2014

Volume 63, Issue 12



## Heart Failure and Cardiomyopathies

### EFFECT OF DIGOXIN ON MORTALITY IN PATIENTS WITH ISOLATED RIGHT VENTRICULAR DYSFUNCTION SECONDARY TO SEVERE PULMONARY HYPERTENSION

Oral Contributions

Room 146 B

Sunday, March 30, 2014, 9:06 a.m.-9:18 a.m.

Session Title: Update from Clinical Trials in Heart Failure: Year in Review

Abstract Category: 14. Heart Failure and Cardiomyopathies: Therapy

Presentation Number: 912-08

Authors: *Parham Eshtehardi, M. Khalid Mojadidi, Khashayar Khosraviani, Mohan Pamerla, Ronald Zolty, Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA, Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA*

**Background:** While digoxin can exert favorable hemodynamic effects in acute right ventricular (RV) failure secondary to pulmonary hypertension (PH), its role in chronic management of these patients is controversial.

**Methods:** From 2002 to 2012, all consecutive patients with age  $\geq 18$  years, severe PH defined by a pulmonary artery systolic pressure  $\geq 65$  mmHg, RV hypokinesis, and left ventricular ejection fraction  $\geq 50\%$  were enrolled from 3 hospitals of Montefiore Medical Center. Patients were divided into two groups based on whether or not they were on digoxin for 12 consecutive months after diagnosis of PH. Primary endpoint was 1-year all-cause mortality and secondary endpoint was 1-year hospital readmission.

**Results:** Of 2,208 patients included (age  $71 \pm 16$ ; 31% male), 166 (8%) patients were on digoxin therapy. In the entire population, 1-year mortality was 32.6% and readmission was 3.6%. Mortality was significantly lower in digoxin group compared to no-digoxin group (25% vs 33%, RR 0.67 [95% CI 0.49, 0.92],  $p=0.02$ ), while readmission rate was not different (3.9 vs. 3.6%, RR 1.64 [95% CI 0.84, 3.18],  $p=NS$ ), Figure. In multivariate analysis adjusted for baseline characteristics, digoxin therapy remained an independent predictor of lower 1-year mortality ( $p<0.02$ ).

**Conclusions:** In a multicenter study, we demonstrated for the first time, that in patients with isolated RV dysfunction secondary to severe PH, digoxin therapy improves the survival by reducing 1-year all-cause mortality.

